Mission Statement: “At Boston Scientific, we work collaboratively to solve healthcare’s toughest challenges by developing solutions that matter most to those suffering from debilitating and life-threatening conditions and the healthcare professionals who provide their care. These forward-looking statements include, among other things, statements regarding new product development, regulatory approval, product performance and our growth strategy. Join Our Team Rewarding Careers Improving Health. "Surgi-Vision is thrilled to have entered into this agreement with Boston Scientific as it represents a tremendous opportunity for both companies," said Kimble Jenkins, Chief Executive Officer of Surgi-Vision. Meaningful Innovation. Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. About Boston Scientific. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. The company will also present its pipeline of innovation in deep brain stimulation (DBS) for the treatment of movement disorders in patients with Parkinson's Disease, dystonia and essential tremor, including the Vercise™ Gevia™ Deep Brain Stimulation System5, which recently received CE mark and is the industry's first MR-conditional directional DBS system with stimulation visualization. SRCD’s mission is rooted in an understanding of child development as an integrated part of lifelong development that takes place in complex and interrelated contexts. All rights reserved. Cardiac Resynchronization Therapy (CRT) Devices, Transcatheter Aortic Valve Replacement (TAVR), Medical Device ID Cards - Pacemaker, ICD, & CRT devices, Remote Patient Monitoring and Diagnostic Monitoring, ADVANTICS™ Innovative Healthcare Solutions. A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included below. Complete archives and summary materials from today's presentations will also be available online for approximately one year. Boston Scientific Corp. and Surgi-Vision Inc. of Baltimore, Md., announced a deal to license and develop magnetic resonance imaging (MRI)-safe technology for implantable cardiac devices. Reports & Filings Annual Results and Proxy Statements Annual Report and … "Our company is a leader in the development of MRI-safe technologies, and we look forward to applying our expertise to the field of cardiac rhythm management devices with Boston Scientific. For more information, please visit: http://www.bostonscientific.com/. Cardiovascular Segment "We are also focused on driving global expansion and further improving profitability so that we can invest in our future portfolio and consistently deliver long term, durable growth.". Mission, Vision, and Values of Boston Scientific. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. Advance your career. Not available for use or sale. 2The ACURATE neo AS Valve System is pending CE Mark. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. ©2020 Boston Scientific Corporation or its affiliates. 1The Lotus Edge Valve System is not available for use or sale. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Core Values. We work collaboratively to pursue global opportunities that extend the reach of our medical solutions. MedSurg Segment  The RHYTHMIA System has launched in more than 25 countries, been used in over 13,000 cases worldwide, and offers five times faster mapping and 25 times the data points over other available technology. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. Shirt... We use cookies to improve user experience and analyze our website traffic as stated in our, Photonics in Defense & Aerospace Newsletter, Nitrogen-Filled Hollow-Core Fiber Moves Laser Spectra to the Infrared, AdvanTech, Quanergy Partner for Lidar-Based Solutions, DARPA Awards Consortium $36M for Spinal Cord Injury Recovery Systems, TRUMPF Reports 8% Fiscal Year-End Sales Decline. Limited by Federal (or U.S.) law to investigational use only. The companies will jointly develop a commercial application of Surgi-Vision's technology. This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. About Boston Scientific  ", "This agreement with Surgi-Vision is consistent with our vision of providing physicians with the highest quality products for their patients," said Fred Colen, Executive Vice President, Operations and Technology, Boston Scientific Cardiac Rhythm Management. For more than 100 years, Boston Medical Center has been driven by a commitment to care for all people, providing not only traditional medical care, but also programs and services that wrap around that care to enhance overall health. "We are executing well on our financial objectives for consistent revenue growth, adjusted operating margin expansion and top tier adjusted earnings growth.". The two companies will work jointly to develop a commercial application of Surgi-Vision's technology. Scientific Vision. Mission: Our group aims at developing a better understanding in several areas of polymer physics and engineering, with an emphasis on dynamics, diffusion, and rheology, related to flow, processing and mechanical properties of polymeric materials. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. The company intends to leverage its existing LOTUS infrastructure to expand the ACURATE neo AS Valve system through increased field support, geographic expansion and next generation products, and plans to invest in U.S. and Japan approval trials. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; disposition of non-strategic assets and, future business decisions made by us and our competitors. Procedures & Treatments Choose the right technology and the right techniques to help improve outcomes — like our laser solutions for treating Stones and BPH. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Interventional Cardiology: Boston Scientific continues to be the U.S. leader in drug-eluting stents with its SYNERGY™ Bioabsorbable Polymer Drug Eluting Stent System for the treatment of coronary artery disease, and a global leader in products for complex percutaneous coronary interventions, intravascular ultrasound imaging and chronic total occlusions. This cautionary statement is applicable to all forward-looking statements contained in this document. ©2019 Boston Scientific Corporation or its affiliates. Read on for a breakdown of the company's mission and vision statements and its core values. Cardiac Rhythm Management: Boston Scientific continues to deliver innovative technologies with global cardiac rhythm management portfolio approvals and launches. The EAP designation is reserved for breakthrough technologies that may offer clinically meaningful advantages over existing alternatives, and is expected to accelerate the market approval of the drug-eluting vascular stent system designed for treatment of critical limb ischemia by approximately two years. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. Learn about living with an implanted device, explore health conditions and treatment options, and get support. Boston Scientific will also review its Men's and Women's Health portfolios, as well as plans to potentially expand globally and into $2.6 billion in new segments such as urologic cancer. The company expects to be able to continue to diversify its portfolio away from low growth markets, which represented nearly 50% of sales in 2012, to moderate and high growth markets, which represented ~60% of sales in 2016 with a goal to reach an estimated 75% of sales by 2020. During today's meeting, Boston Scientific senior leaders will highlight new products and pipeline technologies aligned with the company's goal of category leadership within its Cardiovascular, Rhythm Management and MedSurg segments. Physician implanters have consistently mentioned MRI-safe cardiac devices as a primary unmet clinical need. Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology, Emerging technology will potentially enable access to MRI exams for implantable cardiac device patients, Cardiac Resynchronization Therapy (CRT) Devices, Medical Device ID Cards - Pacemaker, ICD, & CRT devices, Remote Patient Monitoring and Diagnostic Monitoring - Boston Scientific. "Surgi-Vision's technology, when combined with our history of innovation, should move development of MRI-safe cardiac devices closer to reality.". Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. MARLBOROUGH, Mass., June 27, 2017/Updated/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. The company will also discuss plans to provide an Insertable Cardiac Monitor (ICM)3 solution in 2019 with a diagnostic-only device platform designed for cardiac arrhythmia monitoring through a mobile patient interface. Cautionary Statement Regarding Forward-Looking Statements  Electrophysiology: The company will present its cadence of therapeutic portfolio expansion with DirectSense™ technology3 and Force Sensing Technology3 for use with the RHYTHMIATM Mapping System. Read now. Boston Scientific and Surgi-Vision entered into a separate licensing and development agreement, in the area of neuromodulation, in December 2005. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Boston Scientific environment, health and safety (EHS) policy outlines our company’s commitment to protecting the planet and our people, and to incorporating sustainability in the development and adoption of our site operations and practices. Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.